How to approach clinically discordant FT4 results when changing testing platforms: real-world evidence

Giovanella L, Duntas L, D'Aurizio F, Kurka H, Ammer T, Rank CM, Visser WE, Van Den Berg SAA (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Endocrine Springer

DOI: 10.1007/s12020-022-03098-5

Abstract

Purpose Measurement of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) is important for assessing thyroid dysfunction. After changing assay manufacturer, high FT4 versus TSH levels were reported at Ente Ospedaliero Cantonale (EOC; Bellinzona, Switzerland). Methods Exploratory analysis used existing TSH and FT4 measurements taken at EOC during routine clinical practice (February 2018-April 2020) using Elecsys (R) TSH and Elecsys FT4 III immunoassays on cobas (R) 6000 and cobas 8000 analyzers (Roche Diagnostics). Reference intervals (RIs) were estimated using both direct and indirect (refineR algorithm) methods. Results In samples with normal TSH levels, 90.9% of FT4 measurements were within the normal range provided by Roche (12-22 pmol/L). For FT4 measurements, confidence intervals (CIs) for the lower end of the RI obtained using direct and indirect methods were lower than estimated values in the method sheet; the estimated value of the upper end of the RI (UEoRI) in the method sheet was within the CI for the UEoRI using the direct method but not the indirect method. CIs for the direct and indirect methods overlapped at both ends of the RI. The most common cause of increased FT4 with normal TSH was identified in a subset of patients as use of thyroxine therapy (72.6%). Conclusions It is important to verify RIs for FT4 in the laboratory population when changing testing platforms; indirect methods may constitute a convenient tool for this. Applying specific RIs for selected subpopulations should be considered to avoid misinterpretations and inappropriate clinical actions.

Involved external institutions

Ospedale Santa Maria della Misericordia di Udine IT Italy (IT) Ente Ospedaliero Cantonale CH Switzerland (CH) National and Kapodistrian University of Athens GR Greece (GR) Roche Diagnostics GmbH DE Germany (DE) Erasmus University Medical Center (MC) NL Netherlands (NL)

How to cite

APA:

Giovanella, L., Duntas, L., D'Aurizio, F., Kurka, H., Ammer, T., Rank, C.M.,... Van Den Berg, S.A.A. (2022). How to approach clinically discordant FT4 results when changing testing platforms: real-world evidence. Endocrine. https://dx.doi.org/10.1007/s12020-022-03098-5

MLA:

Giovanella, Luca, et al. "How to approach clinically discordant FT4 results when changing testing platforms: real-world evidence." Endocrine (2022).

BibTeX: Download